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REVIEW ARTICLE 
The use of high flow nasal oxygen in COPD patients 
Nicole Sciberras 
High flow nasal oxygen (HFNO) is one of the interventions a physician 
may opt to prescribe in hypoxemic patients. It involves the delivery 
of heated and humidified oxygen at rates of up to 60L/min via large 
bore nasal cannulae in a controlled manner, with variables such as the 
fraction of inspired oxygen (FiO2) which may be controlled 
independently.  The set-up of HFNO consists of an oxygen generator, 
a flow meter, a humidifier and wide bore nasal cannulae (figure 1).   
There are 5 physiologic mechanisms that are believed to be 
responsible for the efficacy of HFNO. These include physiological 
dead space washout of waste gases including carbon dioxide (CO2), 
decreased respiratory rate, positive end-expiratory pressure, 
increased tidal volume and increased end-expiratory volume. These 
mechanisms account for the multiple applications of HFNO in 
hypoxemic patients, both in the acute and chronic settings. The use 
of HFNO in the management of COPD has risen along the years.  It 
plays a role in both acute and stable COPD patients, however, the 
present evidence is insufficient for HFNO to be utilised preferentially 
especially in the acute setting.  Larger scale studies are necessary to 
establish its role especially in these scenarios where NIV is currently 
recommended as the first line mode of oxygenation and HFNO is 
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High flow nasal oxygen (HFNO) is one of the 
interventions a physician may opt to prescribe 
in hypoxemic patients.  It involves the delivery 
of heated and humidified oxygen at rates of up 
to 60L/min via large bore nasal cannulae in a 
controlled manner, with variables such as the 
fraction of inspired oxygen (FiO2) which may 
be controlled independently.  Unlike low flow 
nasal oxygen, the FiO2 is not related to the 
flow rate, and there is the added advantage of 
less air leaks in HFNO.  The set-up of HFNO 
consists of an oxygen generator, a flow meter, 
a humidifier and wide bore nasal cannulae.1 In 
view of delivering the oxygen in a heated, 
humidified manner via nasal cannulae, as 
opposed to cold dry oxygen via a tight fitting 
mask, HFNO may be better tolerated by 
patients in comparison to long term oxygen 
therapy (LTOT) and non-invasive positive 
pressure ventilation (NIPPV).  
SEARCH CRITERIA  
The search for publications and abstracts was 
done electronically on PubMed, the Cochrane 
database of systematic reviews, using the 
search terms: ‘high flow nasal oxygen in 
COPD’. The search was limited to articles 
available in English language, related to human 
subjects and published within the past five 
years.  A total of fifty- five (55) articles were 
identified in this search.  A single reviewer 
(myself) screened all potential references for 
inclusion, which brought the number of 
articles to thirty-one (31). The last update of 
the search was performed in May 2020. 
PHYSIOLOGICAL MECHANISMS 
There are 5 physiologic mechanisms that are 
believed to be responsible for the efficacy of 
HFNO. These include: 
 Physiological dead space washout of waste 
gases including carbon dioxide (CO2) 
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 Decreased respiratory rate 
 Positive end-expiratory pressure 
 Increased tidal volume 
 Increased end-expiratory volume 
These mechanisms account for the multiple 
applications of HFNO in hypoxemic patients, 
both in the acute and chronic settings.  
HFNO confers two advantages in relation to 
the washout of carbon dioxide from the 
physiological dead space, which is increased in 
conditions such as emphysema.  Firstly, nasal 
cannulae do not increase the physiological 
dead space, as happens with masks used in 
other forms of oxygenation.  Secondly, the 
high flow of oxygen washes out the carbon 
dioxide in the upper respiratory tract, as has 
been studied by measuring the CO2 
elimination rate using a dynamic CO2 
spectroscope with infrared radiation and a 
gamma camera.2 The upper respiratory tract is 
one component of the physiological dead 
space, and thus the effect on HFNO on the 
other parts of this dead space, such as the 
bronchioles, is yet to be ascertained.   
Decreased respiratory rate with the use of 
HFNO has been linked to the first mechanism. 
Clearance of carbon dioxide from the 
physiological dead space due to the positive 
end expiratory effect of HFNO results in better 
ventilation-perfusion matching, and this 
decreases the work of breathing and therefore 
respiratory rate.2  
A decrease in the work of breathing may also 
be due to the positive end-expiratory pressure 
(PEEP) effect of HFNO. This arises from the 
high flow rate the nasal cannula achieves, 
which causes resistance against expiratory 
flow and increases airway pressure. The PEEP 
effect of HFNO has been compare to the 
pursed-lip breathing pattern COPD patients 
often adopt.2 This effect is related to the size 
of the nasal prongs, whether the subject’s 
mouth is open or closed, sex, body mass index 
and is directly proportional to the oxygen flow 
rate. 3 
Increased end-expiratory lung impedance has 
been reported with HFNO, suggesting 
increasing volumes and functional residual 
capacity which are more pronounced in 
patients with higher body mass index and not 
related to body position.2 This effect was also 
reported in a small study specifically involving 
stable COPD patients whereby HFNO was 
compared to LTOT.4 This same study reported 
an increase in tidal volume and a decrease in 
respiratory rate, thus supporting the above-
mentioned mechanisms. 
Furthermore, HFNO may improve lung 
epithelial mucociliary clearance as suggested 
by in vitro studies, and this was explored in 
patients with bronchiectasis and COPD with 
positive results including less acute 
exacerbations and fewer hospital admissions. 
However, these studies did not directly link the 
results to improved mucociliary clearance in 
COPD patients.2 
DOMICILIARY HFNO  / HFNO  IN CHRONIC STABLE 
COPD 
In 2017, HFNO was deemed safe to use in the 
short-term in stable COPD patients, where its 
effects were observed when use for one hour.5 
The Aalborg study in 2018 consisted of 200 
COPD patients with chronic hypoxemic 
respiratory failure on LTOT, who were 
randomly assigned LTOT only or LTOT and 
HFNO. The use of HFNO for a daily average of 
6-7hours resulted in a statistically significant 
reduction in acute exacerbations of COPD 
(AECOPD), as well as an improvement in mMRC 
grade from 3 months onwards. 138 patients 
completed the study at twelve months and 
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despite no significant difference in hospital 
admission rates, predicted hospital admission 
rates were lower for the HFNO group 
compared to the control group using amount 
of days on HFNO as an explanatory variable.6  
The post-hoc study involving 100 patients with 
COPD and chronic hypoxic failure confirmed 
this as there were reductions in the number of 
AECOPD, the number of hospitalisations and 
length of stay in patients treated with HFNO 
and LTOT, particularly in those with two or 
more exacerbations in the year prior to 
inclusion in the study. Thus it was concluded 
that dual treatment with HFNO and LTOT 
would be more beneficial to patients with 
frequent exacerbations.7 Hypercapnic patients 
were included in this study, however, no 
correlation between paCO2 and number of 
exacerbations was identified. 
On the other hand, Nagata et al’s cross over 
trial in patients with stable hypercapnic COPD 
showed that six weeks of HFNO with LTOT did 
not improve dyspnoea, yet improved both 
quality of life and hypercapnia when compared 
to LTOT alone.  The commonest adverse event 
with HFNO was nocturnal diaphoresis.8    
CHRONIC HYPERCAPNIC COPD 
In a randomised, multi-centre trial in COPD 
patients with daytime hypercapnia, it was 
observed that paCO2 decreased with the use 
of both HFNO and NIV, but decreased more 
with NIV, thus HFNO should be reserved for 
those intolerant to NIV.9 This reduction in 
paCO2 is flow-dependent.10  
HFNO  IN ACUTE EXACERBATIONS OF COPD   
The first trial of HFNO in patients with 
hypercapnic AECOPD with pH <7.38 who had 
failed NIV was executed in 2018 by Braunlich 
et al. A significant improvement in pH and 
pCO2 was noted, more significantly in those 
with pH <7.35, and hence HFNO was deemed a 
promising alternative in the advent of NIV 
failure.11 Besides the issue of NIV failure, a 
case of successful management of an AECOPD 
was reported in an acidotic, hypercapnic 
patient who benefitted from HFNO as his facial 
structure resulted in severe oxygen leaks 
when using NIV masks.12 
In 2019, Pisani et al identified five trials about 
HFNO in relation to COPD exacerbations, 
which studied a total of 198 subjects with a 
male predominance and all aged over 
70years.13 Unfortunately, patient severity was 
not indicated in some trials, yet the FiO2 
required to achieve target saturations of 88 to 
92% (or 90 to 94% in one study) was accurately 
recorded. Two trials concerned COPD 
exacerbations post-extubation and concluded 
that HFNO, when compared with low flow 
oxygen therapy, significantly decreases the 
neuroventilatory drive and the work of 
breathing in patients with COPD recovering 
from an episode of acute respiratory failure 
after a planned extubation.14 A lower mean 
arterial pressure was reported with NIV, yet no 
differences were identified with respect to 
arterial blood gas values, re-intubation rate, 
duration of invasive mechanical ventilation, 
length of stay at the intensive care unit and 28 
day-mortality.15  
The third trial conducted by Longhini et al 
assessed the effect of HFNO use in patients 
being weaned off NIV.  It was found that whilst 
36.7% failed NIV discontinuation, in those with 
successful discontinuation, NIV was re-started 
in a lower number of individuals who had 
received HFNO in comparison to those 
receiving controlled oxygen therapy (COT).  
The underlying mechanism for its success was 
a reduction in work of breathing without a rise 
in PaCO2, as previously explained.13 
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In patients presenting with severe AECOPD 
with moderate hypercapnic acute respiratory 
failure, 30 day intubation and mortality rates 
were not statistically different with the use of 
HFNO as opposed to NIV.16 In this case, severe 
AECOPD was defined as sudden worsening of 
resting dyspnea, high respiratory rate (>30 
breaths/min), decreased oxygen saturation 
(6.0 kPa) whilst moderate respiratory failure 
referred to pH levels between 7.25 and 7.35 on 
room air.  In a similar cohort of patients, HFNO 
had an acceptable failure rate.17  Another 
study noted a slight reduction in pCO2 levels 
measured transcutaneously when HFNO was 
used in AECOPD compared with standard nasal 
prongs, however, this was not statistically 
significant and there was no specification of 
the patient’s acid-base status.18   
Besides Pisani et al’s analysis of these 5 trials, 
Sun et al enrolled 82 hypercapnic COPD 
patients in acute respiratory failure, and noted 
that HFNO had a lower failure rate than NIV 
despite this observation not reaching 
statistical significance. A significant difference 
was measured with regards to intolerance 
rate, which was higher for NIV. Despite this, no 
difference was detected between the two 
groups in terms of respiratory distress, 
hypoxemia and carbon dioxide retention. 
HFNO had less airway care interventions, less 
dermatological consequences but required a 
longer time of application compared to NIV.  
Another end-point that was measured was 28-
day mortality, whereby no significant 
difference was observed between the two 
groups.19 
Needless to say, in acute hypoxic respiratory 
failure it is essential to determine the cause, 
whilst keeping in mind the patient’s co-
morbidities, functional status and comfort, 
with regular evaluation of the clinical status 
and the need for intubation.20 
HFNO  AT THE EMERGENCY DEPARTMENT 
HFNO causes less dyspnea and is more 
comfortable compared to COT in patients at 
the emergency department with acute 
dyspnea and hypoxemia, which may be 
attributed to COPD.  However, there are 
currently no trials specific to COPD emergency 
presentations, and furthermore, this study did 
not measure FiO2 in COT subjects which is 
important to compare gas exchange especially 
in COPD patients.21  
AEROSOL DELIVERY VIA HFNO 
COPD management may involve the use of 
aerosolised treatment such as salbutamol.  
Inhalation of salbutamol/ipratropium bromide 
solutions via the oral route and HFNO route 
was studied in a population on separate days, 
and no significant post-inhalational 
differences were measured on spirometry.22 
However, HFNO confers the advantage of 
delivering medications without interruption of 
the oxygen supply.  A comparison of the 
different modes of medication administration 
via HFNO cannulae at low flow rates of oxygen 
was drawn by measuring urinary salbutamol 
excretion.  Vibrating mesh nebulisers were 
superior to jet nebulisers, and no additional 
benefit was derived from additionally using a 
spacer with the HFNO cannulae set-up.23 
HFNO  POST-EXTUBATION 
Besides Jing and Di Mussi’s observations 
explored above as AECOPD post- extubation, 
Zhang et al studied HFNO safety in COPD 
patients post-extubation.  HFNO was deemed 
safe to use as it reduced length of stay at ITU, 
did not alter mortality and re-intubation rate, 
and had a similar side-effect incidence when 
compared to NIV.  The only adverse finding 
was that of a higher oxygenation index in the 
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NIV group at twelve hours post-extubation, 
however, this observation did not hold at 24 
and 72hours after extubation.24   
HFNO  DURING SLEEP 
A small prospective study in 2017 assessed the 
effect of oxygen and HFNO on sleep in COPD 
patients with FEV1 >30% predicted and 
smokers as the control.  HFNO was found to be 
advantageous in that it not only reduced the 
work of breathing, but also reduced paCO2, an 
effect not seen when using conventional 
oxygen.25 
In 2018, the above findings were confirmed 
separately by directly measuring CO2 
production using a metabolic hood and 
polysomnography. Two conclusions were 
derived, the first one being that responses in 
ventilation to HFNO during sleep were similar 
in COPD patients and controls. Secondly, the 
physiological mechanisms of HFNO were 
confirmed as the use of HFNO caused a 
substantial decline in minute ventilation due 
to a reduction in dead space ventilation 
without a major change in alveolar ventilation, 
CO2 production, energy expenditure or 
transcutaneous CO2.26 
Later that year, the effect of HFNO on 
sympathetic activity during sleep was 
researched using finger pulse wave amplitude. 
HFNO reduced sympathetic activity in COPD 
patients especially during REM sleep, whilst 
supplemental oxygen did not. This effect was 
not observed in the control group, and was 
observed to a lesser degree in COPD patients 
with forced expiratory volume of greater than 
1.65L.27 
HFNO  AND EXERCISE TOLERANCE  
Exercise intolerance in COPD may be 
attributed to the dead space volume in the 
upper airways, and thus HFNO might play a 
role in this regard.  In a small trial involving 
severe COPD patients with ventilatory 
limitation, the subjects experienced less 
dyspnoea during exercise when using HFNO. 
Other findings were those of increased oxygen 
partial pressure, however, the mechanism for 
these results was not studied.28  
HFNO  IN PALLIATIVE COPD PATIENTS 
In his review of end-of-life respiratory support, 
Davies concludes that in spite of a wide 
evidence base for the use of NIV in this 
context, there is no evidence yet to support 
the use of HFNO, and this lack of evidence is 
not restricted to its use in COPD palliation, but 
also in other conditions.29 
CONCLUSION 
The use of HFNO in the management of COPD 
has risen along the years.30 It plays a role in 
both acute and stable COPD patients, 
however, the present evidence is insufficient 
for HFNO to be utilised preferentially 
especially in the acute setting.31 Larger scale 
studies are necessary to establish its role 
especially in these scenarios where NIV is 
currently recommended as the first line mode 
of oxygenation and HFNO is reserved for those 
unable to tolerate NIV. 
FUTURE DEVELOPMENTS 
Keeping in mind the body of evidence for the 
applications of HFNO in COPD patients which 
was explored in this article, there are still 
applications that need to be addressed or that 
necessitate larger trials to be conducted. One 
such query is posed by Mansfield regarding 
HFNO preceding the use of NIV in AECOPD, as 
well as its use when NIV is not tolerated.32 
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